291 related articles for article (PubMed ID: 14529625)
1. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
Bertrand JA; Thieffine S; Vulpetti A; Cristiani C; Valsasina B; Knapp S; Kalisz HM; Flocco M
J Mol Biol; 2003 Oct; 333(2):393-407. PubMed ID: 14529625
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
3. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
[TBL] [Abstract][Full Text] [Related]
5. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
6. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
[TBL] [Abstract][Full Text] [Related]
7. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
8. Structure-based approaches in the design of GSK-3 selective inhibitors.
Patel DS; Dessalew N; Iqbal P; Bharatam PV
Curr Protein Pept Sci; 2007 Aug; 8(4):352-64. PubMed ID: 17696868
[TBL] [Abstract][Full Text] [Related]
9. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
Coghlan MP; Culbert AA; Cross DA; Corcoran SL; Yates JW; Pearce NJ; Rausch OL; Murphy GJ; Carter PS; Roxbee Cox L; Mills D; Brown MJ; Haigh D; Ward RW; Smith DG; Murray KJ; Reith AD; Holder JC
Chem Biol; 2000 Oct; 7(10):793-803. PubMed ID: 11033082
[TBL] [Abstract][Full Text] [Related]
10. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
Gaisina IN; Gallier F; Ougolkov AV; Kim KH; Kurome T; Guo S; Holzle D; Luchini DN; Blond SY; Billadeau DD; Kozikowski AP
J Med Chem; 2009 Apr; 52(7):1853-63. PubMed ID: 19338355
[TBL] [Abstract][Full Text] [Related]
11. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
[TBL] [Abstract][Full Text] [Related]
13. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer.
Liao X; Thrasher JB; Holzbeierlein J; Stanley S; Li B
Endocrinology; 2004 Jun; 145(6):2941-9. PubMed ID: 14988390
[TBL] [Abstract][Full Text] [Related]
14. Identification of small molecules that inhibit GSK-3beta through virtual screening.
Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
[TBL] [Abstract][Full Text] [Related]
15. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta.
Kunick C; Lauenroth K; Leost M; Meijer L; Lemcke T
Bioorg Med Chem Lett; 2004 Jan; 14(2):413-6. PubMed ID: 14698171
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation.
Neumann M; Klar S; Wilisch-Neumann A; Hollenbach E; Kavuri S; Leverkus M; Kandolf R; Brunner-Weinzierl MC; Klingel K
Oncogene; 2011 May; 30(21):2485-92. PubMed ID: 21217772
[TBL] [Abstract][Full Text] [Related]
17. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
Leost M; Schultz C; Link A; Wu YZ; Biernat J; Mandelkow EM; Bibb JA; Snyder GL; Greengard P; Zaharevitz DW; Gussio R; Senderowicz AM; Sausville EA; Kunick C; Meijer L
Eur J Biochem; 2000 Oct; 267(19):5983-94. PubMed ID: 10998059
[TBL] [Abstract][Full Text] [Related]
18. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β.
Atilla-Gokcumen GE; Di Costanzo L; Meggers E
J Biol Inorg Chem; 2011 Jan; 16(1):45-50. PubMed ID: 20821241
[TBL] [Abstract][Full Text] [Related]
19. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.
Licht-Murava A; Plotkin B; Eisenstein M; Eldar-Finkelman H
J Mol Biol; 2011 Apr; 408(2):366-78. PubMed ID: 21354422
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays.
Balboni B; Tripathi SK; Veronesi M; Russo D; Penna I; Giabbai B; Bandiera T; Storici P; Girotto S; Cavalli A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
